

Human Papillomavirus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/H97366AB0703EN.html>

Date: May 2024

Pages: 133

Price: US\$ 6,499.00 (Single User License)

ID: H97366AB0703EN

Abstracts

The 7 major human papillomavirus markets are expected to exhibit a CAGR of 8.33% during 2024-2034.

The human papillomavirus market has been comprehensively analyzed in IMARC's new report titled "Human Papillomavirus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Human papillomavirus (HPV) refers to a common sexually transmitted infection that affects both men and women. It is mainly characterized by the presence of skin or mucous membrane growths (warts) in various parts of the body. The disease is primarily spread through skin-to-skin contact or sexual intercourse, including vaginal, anal, and oral sex. Some of the common symptoms associated with HPV are itching, discomfort, pain, breathing difficulty, a burning sensation in the affected area, etc. This ailment can also increase the likelihood of penile, cervical, vaginal, vulvar, anal, mouth, and throat cancers. The diagnosis of the illness typically involves a combination of clinical examination, medical history, and specific investigations. A healthcare provider may perform a visual inspection of the affected areas to look for any signs of HPV infection, such as genital warts. Additionally, a pap smear test is also utilized to detect abnormal cervical cells that might be causing the underlying indications. If there are suspicious lesions, a tissue biopsy is further recommended to evaluate the type and severity of the ailment.

The increasing cases of unprotected sex or skin damage, which can enhance the risk of viral transmission among individuals, are primarily driving the human papillomavirus market. In addition to this, the rising incidences of weakened immune systems due to HIV/AIDS, chronic lifestyle disorders, the use of immunosuppressant medications, etc., are also creating a positive outlook for the market. Moreover, the widespread adoption

of loop electrosurgical excision procedure, which utilizes a thin wire loop heated by an electrical current to excise the affected tissue while causing minimal damage to surrounding healthy cells, is further bolstering the market growth. Apart from this, the inflating application of topical therapeutic agents containing imiquimod or podophyllin to stimulate the production of cytokines, like interferon-alpha, that can enhance the immune response against HPV infection is acting as another significant growth-inducing factor. Additionally, the emerging popularity of cryotherapy on account of its numerous advantages over conventional surgeries, such as targeted destruction of lesions and reduced risk of noticeable scarring, is expected to drive the human papillomavirus market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the human papillomavirus market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for human papillomavirus and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the human papillomavirus market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the human papillomavirus market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the human papillomavirus market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current human papillomavirus marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the human papillomavirus market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the human papillomavirus market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the human papillomavirus market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of human papillomavirus across the seven major markets?

What is the number of prevalent cases (2018-2034) of human papillomavirus by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of human papillomavirus by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with human papillomavirus across the seven major markets?

What is the size of the human papillomavirus patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of human papillomavirus?

What will be the growth rate of patients across the seven major markets?

Human Papillomavirus: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for human papillomavirus drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the human papillomavirus market?

What are the key regulatory events related to the human papillomavirus market?

What is the structure of clinical trial landscape by status related to the human papillomavirus market?

What is the structure of clinical trial landscape by phase related to the human papillomavirus market?

What is the structure of clinical trial landscape by route of administration related to the human papillomavirus market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 HUMAN PAPILLOMAVIRUS - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 HUMAN PAPILLOMAVIRUS - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 HUMAN PAPILLOMAVIRUS - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 HUMAN PAPILLOMAVIRUS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 HUMAN PAPILLOMAVIRUS - UNMET NEEDS

10 HUMAN PAPILLOMAVIRUS - KEY ENDPOINTS OF TREATMENT

11 HUMAN PAPILLOMAVIRUS - MARKETED PRODUCTS

- 11.1 List of Human Papillomavirus Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) - Merck & Co.
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
 - 11.1.2 Cervarix (Human papillomavirus vaccine recombinant bivalent) -

GlaxoSmithKline

- 11.1.2.1 Drug Overview
- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 HUMAN PAPILLOMAVIRUS - PIPELINE DRUGS

12.1 List of Human Papillomavirus Pipeline Drugs Across the Top 7 Markets

- 12.1.1 Drug Name - Company Name
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

13. HUMAN PAPILLOMAVIRUS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. HUMAN PAPILLOMAVIRUS – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 HUMAN PAPILLOMAVIRUS - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Human Papillomavirus - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
 - 15.2.2 Human Papillomavirus - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)

- 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Human Papillomavirus - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Human Papillomavirus - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Human Papillomavirus - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Human Papillomavirus - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Human Papillomavirus - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Human Papillomavirus - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Human Papillomavirus - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Human Papillomavirus - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Human Papillomavirus - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Human Papillomavirus - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Human Papillomavirus - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Human Papillomavirus - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Human Papillomavirus - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Human Papillomavirus - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)

- 15.7.2.2 Market Forecast by Therapies (2024-2034)
- 15.7.3 Human Papillomavirus - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Human Papillomavirus - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Human Papillomavirus - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Human Papillomavirus - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Human Papillomavirus - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Human Papillomavirus - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Human Papillomavirus - Access and Reimbursement Overview

16 HUMAN PAPILOMAVIRUS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 HUMAN PAPILOMAVIRUS MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 HUMAN PAPILOMAVIRUS MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Human Papillomavirus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/H97366AB0703EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H97366AB0703EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

